NextCure, Inc. (NXTC) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US65343E2072
NextCure, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -57.62 m USD |
| EBIT | -55.84 m USD |
| Net income | -55.84 m USD |
| Diluted EPS – continuing operations | -19.65 USD |
Full history since 2017, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About NextCure, Inc.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Baltimore, Maryland.
More stocks
- BriaCell Therapeutics Corp. (BCTX)
- ProMIS Neurosciences Inc. (PMN)
- RYTHM, Inc. (RYM)
- Quest Resource Holding Corp (QRHC)
- Kestrel Group Ltd (KG)
- Grandstand Limited (GRSD)
- Zhanling International Ltd (ZLME)
- Pelthos Therapeutics Inc. (PTHS)
- Bluerock Homes Trust, Inc. (BHM)
- Aardvark Therapeutics, Inc. (AARD)
- RAPID MICRO BIOSYSTEMS, INC. (RPID)
- COFFEE HOLDING CO INC (JVA)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.